{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T20:16:18Z","timestamp":1768594578109,"version":"3.49.0"},"reference-count":87,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2017,9,21]],"date-time":"2017-09-21T00:00:00Z","timestamp":1505952000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Neurol"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1007\/s11940-017-0473-2","type":"journal-article","created":{"date-parts":[[2017,9,21]],"date-time":"2017-09-21T01:09:05Z","timestamp":1505956145000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Treatment Opportunities in Patients With Metabolic Myopathies"],"prefix":"10.1007","volume":"19","author":[{"given":"Mette Cathrine","family":"\u00d8rngreen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Vissing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,9,21]]},"reference":[{"key":"473_CR1","doi-asserted-by":"crossref","unstructured":"\u00d8rngreen M and Vissing J. Metabolic myopathies in Oxford textbook of neuromuscular disorders. First edition. ed. Oxford textbooks in clinical neurology. Oxford: Oxford University Press; 2014.","DOI":"10.1093\/med\/9780199698073.003.0029"},{"issue":"2","key":"473_CR2","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/ana.410170216","volume":"17","author":"RG Haller","year":"1985","unstructured":"Haller RG, et al. Myophosphorylase deficiency impairs muscle oxidative metabolism. Ann Neurol. 1985;17(2):196\u20139.","journal-title":"Ann Neurol"},{"issue":"2","key":"473_CR3","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S1071-9091(96)80038-6","volume":"3","author":"I Tein","year":"1996","unstructured":"Tein I. Metabolic myopathies. Semin Pediatr Neurol. 1996;3(2):59\u201398.","journal-title":"Semin Pediatr Neurol"},{"issue":"26","key":"473_CR4","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1056\/NEJMoa031836","volume":"349","author":"J Vissing","year":"2003","unstructured":"Vissing J, Haller RG. The effect of oral sucrose on exercise tolerance in patients with McArdle\u2019s disease. N Engl J Med. 2003;349(26):2503\u20139.","journal-title":"N Engl J Med"},{"issue":"6","key":"473_CR5","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1001\/archneur.65.6.786","volume":"65","author":"ST Andersen","year":"2008","unstructured":"Andersen ST, Haller RG, Vissing J. Effect of oral sucrose shortly before exercise on work capacity in McArdle disease. Arch Neurol. 2008;65(6):786\u20139.","journal-title":"Arch Neurol"},{"issue":"12","key":"473_CR6","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1136\/adc.2008.146548","volume":"79","author":"ST Andersen","year":"2008","unstructured":"Andersen ST, Vissing J. Carbohydrate- and protein-rich diets in McArdle disease: effects on exercise capacity. J Neurol Neurosurg Psychiatry. 2008;79(12):1359\u201363.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"7","key":"473_CR7","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1001\/archneur.57.7.956","volume":"57","author":"M Vorgerd","year":"2000","unstructured":"Vorgerd M, et al. Creatine therapy in myophosphorylase deficiency (McArdle disease): a placebo-controlled crossover trial. Arch Neurol. 2000;57(7):956\u201363.","journal-title":"Arch Neurol"},{"issue":"7","key":"473_CR8","doi-asserted-by":"crossref","first-page":"E1235","DOI":"10.1210\/jc.2013-1651","volume":"98","author":"N Preisler","year":"2013","unstructured":"Preisler N, et al. Fat and carbohydrate metabolism during exercise in phosphoglucomutase type 1 deficiency. J Clin Endocrinol Metab. 2013;98(7):E1235\u201340.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"473_CR9","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.nmd.2017.01.014","volume":"27","author":"NC Voermans","year":"2017","unstructured":"\u2022\u2022 Voermans NC, et al. PGM1 deficiency: substrate use during exercise and effect of treatment with galactose. Neuromuscul Disord. 2017;27(4):370\u20136. This study indicates that oral supplementation of galactose is beneficial in patients with phosphoglucomutase 1 deficiency.","journal-title":"Neuromuscul Disord"},{"issue":"15","key":"473_CR10","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa0909859","volume":"362","author":"AT Ploeg van der","year":"2010","unstructured":"van der Ploeg AT, et al. A randomized study of alglucosidase alfa in late-onset Pompe\u2019s disease. N Engl J Med. 2010;362(15):1396\u2013406.","journal-title":"N Engl J Med"},{"issue":"7","key":"473_CR11","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1097\/GIM.0b013e3181e655b6","volume":"12","author":"PS Kishnani","year":"2010","unstructured":"Kishnani PS, et al. Glycogen storage disease type III diagnosis and management guidelines. Genet Med. 2010;12(7):446\u201363.","journal-title":"Genet Med"},{"issue":"1","key":"473_CR12","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ymgme.2013.02.008","volume":"109","author":"N Preisler","year":"2013","unstructured":"Preisler N, et al. Exercise intolerance in glycogen storage disease type III: weakness or energy deficiency? Mol Genet Metab. 2013;109(1):14\u201320.","journal-title":"Mol Genet Metab"},{"issue":"7","key":"473_CR13","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1212\/WNL.59.7.1046","volume":"59","author":"MC Orngreen","year":"2002","unstructured":"Orngreen MC, Olsen DB, Vissing J. Exercise tolerance in carnitine palmitoyltransferase II deficiency with IV and oral glucose. Neurology. 2002;59(7):1046\u201351.","journal-title":"Neurology"},{"issue":"4","key":"473_CR14","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1212\/01.WNL.0000078195.05396.20","volume":"61","author":"MC Orngreen","year":"2003","unstructured":"Orngreen MC, Ejstrup R, Vissing J. Effect of diet on exercise tolerance in carnitine palmitoyltransferase II deficiency. Neurology. 2003;61(4):559\u201361.","journal-title":"Neurology"},{"issue":"3","key":"473_CR15","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1002\/ajmg.10585","volume":"111","author":"AM Lamhonwah","year":"2002","unstructured":"Lamhonwah AM, et al. Novel OCTN2 mutations: no genotype-phenotype correlations: early carnitine therapy prevents cardiomyopathy. Am J Med Genet. 2002;111(3):271\u201384.","journal-title":"Am J Med Genet"},{"issue":"Pt 8","key":"473_CR16","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1093\/brain\/awm135","volume":"130","author":"RK Olsen","year":"2007","unstructured":"Olsen RK, et al. ETFDH mutations as a major cause of riboflavin-responsive multiple acyl-CoA dehydrogenation deficiency. Brain. 2007;130(Pt 8):2045\u201354.","journal-title":"Brain"},{"issue":"Pt 8","key":"473_CR17","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1093\/brain\/awm054","volume":"130","author":"K Gempel","year":"2007","unstructured":"Gempel K, et al. The myopathic form of coenzyme Q10 deficiency is caused by mutations in the electron-transferring-flavoprotein dehydrogenase (ETFDH) gene. Brain. 2007;130(Pt 8):2037\u201344.","journal-title":"Brain"},{"issue":"11","key":"473_CR18","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.nmd.2010.06.018","volume":"20","author":"P Laforet","year":"2010","unstructured":"Laforet P, Vianey-Saban C. Disorders of muscle lipid metabolism: diagnostic and therapeutic challenges. Neuromuscul Disord. 2010;20(11):693\u2013700.","journal-title":"Neuromuscul Disord"},{"issue":"6","key":"473_CR19","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1136\/jclinpath-2014-202808","volume":"68","author":"SE Olpin","year":"2015","unstructured":"\u2022\u2022 Olpin SE, et al. The investigation and management of metabolic myopathies. J Clin Pathol. 2015;68(6):410\u20137. This review summarizes the diagnostic process and management of patients with metabolic myopathies.","journal-title":"J Clin Pathol"},{"issue":"1","key":"473_CR20","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1056\/NEJMra0801327","volume":"361","author":"X Bosch","year":"2009","unstructured":"Bosch X, Poch E, Grau JM. Rhabdomyolysis and acute kidney injury. N Engl J Med. 2009;361(1):62\u201372.","journal-title":"N Engl J Med"},{"issue":"6","key":"473_CR21","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1515\/CCLM.2010.151","volume":"48","author":"G Cervellin","year":"2010","unstructured":"Cervellin G, Comelli I, Lippi G. Rhabdomyolysis: historical background, clinical, diagnostic and therapeutic features. Clin Chem Lab Med. 2010;48(6):749\u201356.","journal-title":"Clin Chem Lab Med"},{"issue":"9","key":"473_CR22","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1001\/archneur.59.9.1395","volume":"59","author":"RG Haller","year":"2002","unstructured":"Haller RG, Vissing J. Spontaneous \u201csecond wind\u201d and glucose-induced second \u201csecond wind\u201d in McArdle disease: oxidative mechanisms. Arch Neurol. 2002;59(9):1395\u2013402.","journal-title":"Arch Neurol"},{"issue":"1","key":"473_CR23","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1212\/WNL.62.1.82","volume":"62","author":"RG Haller","year":"2004","unstructured":"Haller RG, Vissing J. No spontaneous second wind in muscle phosphofructokinase deficiency. Neurology. 2004;62(1):82\u20136.","journal-title":"Neurology"},{"issue":"1","key":"473_CR24","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1152\/jappl.1991.70.1.391","volume":"70","author":"SF Lewis","year":"1991","unstructured":"Lewis SF, Vora S, Haller RG. Abnormal oxidative metabolism and O2 transport in muscle phosphofructokinase deficiency. J Appl Physiol (1985). 1991;70(1):391\u20138.","journal-title":"J Appl Physiol (1985)"},{"issue":"1","key":"473_CR25","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1002\/ana.20320","volume":"57","author":"MC Orngreen","year":"2005","unstructured":"Orngreen MC, et al. Fuel utilization in subjects with carnitine palmitoyltransferase 2 gene mutations. Ann Neurol. 2005;57(1):60\u20136.","journal-title":"Ann Neurol"},{"issue":"8","key":"473_CR26","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1212\/01.wnl.0000343002.74480.e4","volume":"72","author":"MC Orngreen","year":"2009","unstructured":"Orngreen MC, et al. Fat metabolism during exercise in patients with McArdle disease. Neurology. 2009;72(8):718\u201324.","journal-title":"Neurology"},{"issue":"2","key":"473_CR27","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/ana.20168","volume":"56","author":"MC Orngreen","year":"2004","unstructured":"Orngreen MC, et al. Fuel utilization in patients with very long-chain acyl-coa dehydrogenase deficiency. Ann Neurol. 2004;56(2):279\u201383.","journal-title":"Ann Neurol"},{"issue":"20","key":"473_CR28","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1212\/01.wnl.0000289190.66955.67","volume":"70","author":"MC Orngreen","year":"2008","unstructured":"Orngreen MC, et al. Is muscle glycogenolysis impaired in X-linked phosphorylase b kinase deficiency? Neurology. 2008;70(20):1876\u201382.","journal-title":"Neurology"},{"issue":"6","key":"473_CR29","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1001\/archneurol.2009.93","volume":"66","author":"ST Andersen","year":"2009","unstructured":"Andersen ST, et al. Effect of changes in fat availability on exercise capacity in McArdle disease. Arch Neurol. 2009;66(6):762\u20136.","journal-title":"Arch Neurol"},{"issue":"7","key":"473_CR30","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1212\/WNL.0000000000000118","volume":"82","author":"MC Orngreen","year":"2014","unstructured":"\u2022\u2022 Orngreen MC, et al. Bezafibrate in skeletal muscle fatty acid oxidation disorders: a randomized clinical trial. Neurology. 2014;82(7):607\u201313. This randomized, double-blind, controlled study of Bezafibrate vs. placebo in 10 patients with the fatty acid oxidation defects VLCAD and CPT II deficiencies showed no improvement of FAO neither at rest or during exercise.","journal-title":"Neurology"},{"issue":"9","key":"473_CR31","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1001\/archneur.62.9.1440","volume":"62","author":"J Vissing","year":"2005","unstructured":"Vissing J, Quistorff B, Haller RG. Effect of fuels on exercise capacity in muscle phosphoglycerate mutase deficiency. Arch Neurol. 2005;62(9):1440\u20133.","journal-title":"Arch Neurol"},{"issue":"10","key":"473_CR32","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.neurol.2016.08.005","volume":"172","author":"J Vissing","year":"2016","unstructured":"Vissing J. Exercise training in metabolic myopathies. Rev Neurol (Paris). 2016;172(10):559\u201365.","journal-title":"Rev Neurol (Paris)"},{"issue":"4","key":"473_CR33","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/JSM.0b013e3180f6168c","volume":"17","author":"JL Mate-Munoz","year":"2007","unstructured":"Mate-Munoz JL, et al. Favorable responses to acute and chronic exercise in McArdle patients. Clin J Sport Med. 2007;17(4):297\u2013303.","journal-title":"Clin J Sport Med"},{"issue":"6","key":"473_CR34","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1002\/ana.20881","volume":"59","author":"RG Haller","year":"2006","unstructured":"Haller RG, et al. Aerobic conditioning: an effective therapy in McArdle\u2019s disease. Ann Neurol. 2006;59(6):922\u20138.","journal-title":"Ann Neurol"},{"issue":"1","key":"473_CR35","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.scispo.2004.11.001","volume":"20","author":"K Ollivier","year":"2005","unstructured":"Ollivier K, et al. Effects of an endurance training on patients with McArdle\u2019s disease. Sci Sports. 2005;20(1):21\u20136.","journal-title":"Sci Sports"},{"issue":"5","key":"473_CR36","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1002\/mus.20251","volume":"31","author":"K Ollivier","year":"2005","unstructured":"Ollivier K, et al. Exercise tolerance and daily life in McArdle\u2019s disease. Muscle Nerve. 2005;31(5):637\u201341.","journal-title":"Muscle Nerve"},{"issue":"3","key":"473_CR37","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1136\/jnnp-2011-301593","volume":"83","author":"A Lucia","year":"2012","unstructured":"Lucia A, et al. Genotypic and phenotypic features of McArdle disease: insights from the Spanish national registry. J Neurol Neurosurg Psychiatry. 2012;83(3):322\u20138.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"473_CR38","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s13023-015-0303-0","volume":"10","author":"LE Berg van den","year":"2015","unstructured":"van den Berg LE, et al. Safety and efficacy of exercise training in adults with Pompe disease: evaluation of endurance, muscle strength and core stability before and after a 12 week training program. Orphanet J Rare Dis. 2015;10:87.","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"473_CR39","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.ymgme.2011.05.013","volume":"104","author":"G Terzis","year":"2011","unstructured":"Terzis G, et al. Effect of aerobic and resistance exercise training on late-onset Pompe disease patients receiving enzyme replacement therapy. Mol Genet Metab. 2011;104(3):279\u201383.","journal-title":"Mol Genet Metab"},{"key":"473_CR40","doi-asserted-by":"crossref","first-page":"334","DOI":"10.3389\/fnagi.2014.00334","volume":"6","author":"A Santalla","year":"2014","unstructured":"Santalla A, et al. Feasibility of resistance training in adult McArdle patients: clinical outcomes and muscle strength and mass benefits. Front Aging Neurosci. 2014;6:334.","journal-title":"Front Aging Neurosci"},{"key":"473_CR41","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/0002-9343(61)90075-4","volume":"30","author":"CM Pearson","year":"1961","unstructured":"Pearson CM, Rimer DG, Mommaerts WF. A metabolic myopathy due to absence of muscle phosphorylase. Am J Med. 1961;30:502\u201317.","journal-title":"Am J Med"},{"issue":"4","key":"473_CR42","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1056\/NEJMc0901158","volume":"361","author":"T Stojkovic","year":"2009","unstructured":"Stojkovic T, et al. Muscle glycogenosis due to phosphoglucomutase 1 deficiency. N Engl J Med. 2009;361(4):425\u20137.","journal-title":"N Engl J Med"},{"issue":"4","key":"473_CR43","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1212\/WNL.0b013e31824365f9","volume":"78","author":"N Preisler","year":"2012","unstructured":"Preisler N, et al. Muscle phosphorylase kinase deficiency: a neutral metabolic variant or a disease? Neurology. 2012;78(4):265\u20138.","journal-title":"Neurology"},{"key":"473_CR44","doi-asserted-by":"crossref","unstructured":"Laforet PO, Orngreen MC; Preisler N; Andersen, G; Vissing, J, Muscle fat oxidation is blocked during exercise in neutral lipid storage disease. Arch Neurol. 2012.","DOI":"10.1001\/archneurol.2011.631"},{"issue":"3","key":"473_CR45","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1212\/01.wnl.0000265854.41013.84","volume":"69","author":"MC Orngreen","year":"2007","unstructured":"Orngreen MC, et al. Effects of IV glucose and oral medium-chain triglyceride in patients with VLCAD deficiency. Neurology. 2007;69(3):313\u20135.","journal-title":"Neurology"},{"issue":"6","key":"473_CR46","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1056\/NEJM199102073240603","volume":"324","author":"RG Haller","year":"1991","unstructured":"Haller RG, Lewis SF. Glucose-induced exertional fatigue in muscle phosphofructokinase deficiency. N Engl J Med. 1991;324(6):364\u20139.","journal-title":"N Engl J Med"},{"issue":"3","key":"473_CR47","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1249\/MSS.0b013e31890eb86","volume":"41","author":"NR Rodriguez","year":"2009","unstructured":"Rodriguez NR, Di Marco NM, Langley S. American College of Sports Medicine position stand. Nutrition and athletic performance. Med Sci Sports Exerc. 2009;41(3):709\u201331.","journal-title":"Med Sci Sports Exerc"},{"issue":"2\u20133","key":"473_CR48","first-page":"332","volume":"29","author":"CR Roe","year":"2006","unstructured":"Roe CR, Mochel F. Anaplerotic diet therapy in inherited metabolic disease: therapeutic potential. J Inherit Metab Dis. 2006;29(2\u20133):332\u201340.","journal-title":"J Inherit Metab Dis"},{"issue":"2","key":"473_CR49","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1172\/JCI0215311","volume":"110","author":"CR Roe","year":"2002","unstructured":"Roe CR, et al. Treatment of cardiomyopathy and rhabdomyolysis in long-chain fat oxidation disorders using an anaplerotic odd-chain triglyceride. J Clin Invest. 2002;110(2):259\u201369.","journal-title":"J Clin Invest"},{"issue":"4","key":"473_CR50","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1212\/01.wnl.0000318283.42961.e9","volume":"71","author":"CR Roe","year":"2008","unstructured":"Roe CR, et al. Carnitine palmitoyltransferase II deficiency: successful anaplerotic diet therapy. Neurology. 2008;71(4):260\u20134.","journal-title":"Neurology"},{"key":"473_CR51","first-page":"322","volume-title":"Textbook of biochemistry with clinical correlations","author":"RA Harris","year":"1997","unstructured":"Harris RA, Devlin TM. Textbook of biochemistry with clinical correlations. New York: Wiley-Liss; 1997. p. 322\u20133."},{"key":"473_CR52","doi-asserted-by":"crossref","unstructured":"Farshidfar F, Pinder MA, and Myrie SB, Creatine supplementation and skeletal muscle metabolism for building muscle mass\u2014review of the potential mechanisms of action. Curr Protein Pept Sci. 2017.","DOI":"10.2174\/1389203718666170606105108"},{"issue":"1","key":"473_CR53","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1001\/archneur.59.1.97","volume":"59","author":"M Vorgerd","year":"2002","unstructured":"Vorgerd M, et al. Effect of high-dose creatine therapy on symptoms of exercise intolerance in McArdle disease: double-blind, placebo-controlled crossover study. Arch Neurol. 2002;59(1):97\u2013101.","journal-title":"Arch Neurol"},{"issue":"2","key":"473_CR54","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/ajmg.c.30087","volume":"142C","author":"N Longo","year":"2006","unstructured":"Longo N, Amat C. di San Filippo, and M. Pasquali, Disorders of carnitine transport and the carnitine cycle. Am J Med Genet C Semin Med Genet. 2006;142C(2):77\u201385.","journal-title":"Am J Med Genet C Semin Med Genet"},{"issue":"5","key":"473_CR55","first-page":"351","volume":"28","author":"HR Scholte","year":"1990","unstructured":"Scholte HR, et al. Primary carnitine deficiency. J Clin Chem Clin Biochem. 1990;28(5):351\u20137.","journal-title":"J Clin Chem Clin Biochem"},{"issue":"4","key":"473_CR56","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1210\/jc.2012-3791","volume":"98","author":"KL Madsen","year":"2013","unstructured":"Madsen KL, et al. Patients with medium-chain acyl-coenzyme a dehydrogenase deficiency have impaired oxidation of fat during exercise but no effect of L-carnitine supplementation. J Clin Endocrinol Metab. 2013;98(4):1667\u201375.","journal-title":"J Clin Endocrinol Metab"},{"issue":"15","key":"473_CR57","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.2169\/internalmedicine.49.3525","volume":"49","author":"R Izumi","year":"2010","unstructured":"Izumi R, et al. A case of McArdle disease: efficacy of vitamin B6 on fatigability and impaired glycogenolysis. Intern Med. 2010;49(15):1623\u20135.","journal-title":"Intern Med"},{"issue":"3","key":"473_CR58","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1002\/mus.22290","volume":"45","author":"S Sato","year":"2012","unstructured":"Sato S, et al. Confirmation of the efficacy of vitamin B6 supplementation for McArdle disease by follow-up muscle biopsy. Muscle Nerve. 2012;45(3):436\u201340.","journal-title":"Muscle Nerve"},{"key":"473_CR59","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Quinlivan R, Martinuzzi A, and Schoser B. Pharmacological and nutritional treatment for McArdle disease (glycogen storage disease type V). Cochrane Database Syst Rev. 2014;(11):CD003458. This Cochrane review critically and thoroughly examine existing treatment studies in patients with McArdle disease.","DOI":"10.1002\/14651858.CD003458.pub5"},{"issue":"6","key":"473_CR60","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1152\/japplphysiol.00118.2003","volume":"95","author":"B Vistisen","year":"2003","unstructured":"Vistisen B, et al. Minor amounts of plasma medium-chain fatty acids and no improved time trial performance after consuming lipids. J Appl Physiol. 2003;95(6):2434\u201343.","journal-title":"J Appl Physiol"},{"issue":"1","key":"473_CR61","first-page":"61","volume":"26","author":"M Vorgerd","year":"2007","unstructured":"Vorgerd M, Zange J. Treatment of glycogenosys type V (McArdle disease) with creatine and ketogenic diet with clinical scores and with 31P-MRS on working leg muscle. Acta Myol. 2007;26(1):61\u20133.","journal-title":"Acta Myol"},{"issue":"6","key":"473_CR62","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1161\/01.CIR.92.6.1387","volume":"92","author":"AH Danser","year":"1995","unstructured":"Danser AH, et al. Angiotensin-converting enzyme in the human heart. Effect of the deletion\/insertion polymorphism. Circulation. 1995;92(6):1387\u20138.","journal-title":"Circulation"},{"issue":"4","key":"473_CR63","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/ana.10499","volume":"53","author":"A Martinuzzi","year":"2003","unstructured":"Martinuzzi A, et al. Phenotype modulators in myophosphorylase deficiency. Ann Neurol. 2003;53(4):497\u2013502.","journal-title":"Ann Neurol"},{"issue":"1","key":"473_CR64","first-page":"64","volume":"26","author":"A Martinuzzi","year":"2007","unstructured":"Martinuzzi A, et al. Chronic therapy for McArdle disease: the randomized trial with ACE inhibitor. Acta Myol. 2007;26(1):64\u20136.","journal-title":"Acta Myol"},{"issue":"10","key":"473_CR65","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1093\/hmg\/ddr089","volume":"20","author":"J Bastin","year":"2011","unstructured":"Bastin J, Lopes-Costa A, Djouadi F. Exposure to resveratrol triggers pharmacological correction of fatty acid utilization in human fatty acid oxidation-deficient fibroblasts. Hum Mol Genet. 2011;20(10):2048\u201357.","journal-title":"Hum Mol Genet"},{"issue":"6","key":"473_CR66","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/nrd2060","volume":"5","author":"JA Baur","year":"2006","unstructured":"Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov. 2006;5(6):493\u2013506.","journal-title":"Nat Rev Drug Discov"},{"key":"473_CR67","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1146\/annurev.med.53.082901.104018","volume":"53","author":"J Berger","year":"2002","unstructured":"Berger J, Moller DE. The mechanisms of action of PPARs. Annu Rev Med. 2002;53:409\u201335.","journal-title":"Annu Rev Med"},{"key":"473_CR68","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/j.1749-6632.1996.tb18619.x","volume":"804","author":"T Lemberger","year":"1996","unstructured":"Lemberger T, et al. PPAR tissue distribution and interactions with other hormone-signaling pathways. Ann N Y Acad Sci. 1996;804:231\u201351.","journal-title":"Ann N Y Acad Sci"},{"key":"473_CR69","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1146\/annurev.cellbio.12.1.335","volume":"12","author":"T Lemberger","year":"1996","unstructured":"Lemberger T, Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: a nuclear receptor signaling pathway in lipid physiology. Annu Rev Cell Dev Biol. 1996;12:335\u201363.","journal-title":"Annu Rev Cell Dev Biol"},{"issue":"4","key":"473_CR70","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/BF00625805","volume":"17","author":"U Abshagen","year":"1980","unstructured":"Abshagen U, Sporl-Radun S, Marinow J. Steady-state kinetics of bezafibrate and clofibrate in healthy female volunteers. Eur J Clin Pharmacol. 1980;17(4):305\u20138.","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"473_CR71","doi-asserted-by":"crossref","first-page":"539","DOI":"10.2165\/00003495-198733060-00002","volume":"33","author":"JP Monk","year":"1987","unstructured":"Monk JP, Todd PA. Bezafibrate. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hyperlipidaemia. Drugs. 1987;33(6):539\u201376.","journal-title":"Drugs"},{"issue":"3","key":"473_CR72","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1210\/jc.2004-1936","volume":"90","author":"F Djouadi","year":"2005","unstructured":"Djouadi F, et al. Peroxisome proliferator activated receptor delta (PPARdelta) agonist but not PPARalpha corrects carnitine palmitoyl transferase 2 deficiency in human muscle cells. J Clin Endocrinol Metab. 2005;90(3):1791\u20137.","journal-title":"J Clin Endocrinol Metab"},{"issue":"18","key":"473_CR73","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1093\/hmg\/ddi303","volume":"14","author":"F Djouadi","year":"2005","unstructured":"Djouadi F, et al. Bezafibrate increases very-long-chain acyl-CoA dehydrogenase protein and mRNA expression in deficient fibroblasts and is a potential therapy for fatty acid oxidation disorders. Hum Mol Genet. 2005;14(18):2695\u2013703.","journal-title":"Hum Mol Genet"},{"issue":"2\u20133","key":"473_CR74","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s10545-006-0266-3","volume":"29","author":"F Djouadi","year":"2006","unstructured":"Djouadi F, et al. Potential of fibrates in the treatment of fatty acid oxidation disorders: revival of classical drugs? J Inherit Metab Dis. 2006;29(2\u20133):341\u20132.","journal-title":"J Inherit Metab Dis"},{"issue":"8","key":"473_CR75","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1056\/NEJMc0806334","volume":"360","author":"JP Bonnefont","year":"2009","unstructured":"Bonnefont JP, et al. Bezafibrate for an inborn mitochondrial beta-oxidation defect. N Engl J Med. 2009;360(8):838\u201340.","journal-title":"N Engl J Med"},{"issue":"1","key":"473_CR76","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/clpt.2010.55","volume":"88","author":"JP Bonnefont","year":"2010","unstructured":"Bonnefont JP, et al. Long-term follow-up of bezafibrate treatment in patients with the myopathic form of carnitine palmitoyltransferase 2 deficiency. Clin Pharmacol Ther. 2010;88(1):101\u20138.","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"473_CR77","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1212\/01.wnl.0000194212.31318.fc","volume":"66","author":"A Schroers","year":"2006","unstructured":"Schroers A, et al. Gentamicin treatment in McArdle disease: failure to correct myophosphorylase deficiency. Neurology. 2006;66(2):285\u20136.","journal-title":"Neurology"},{"issue":"4","key":"473_CR78","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.nurt.2008.08.006","volume":"5","author":"M Vorgerd","year":"2008","unstructured":"Vorgerd M. Therapeutic options in other metabolic myopathies. Neurotherapeutics. 2008;5(4):579\u201382.","journal-title":"Neurotherapeutics"},{"issue":"5","key":"473_CR79","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1097\/WCO.0b013e328364dbdc","volume":"26","author":"A Oldfors","year":"2013","unstructured":"Oldfors A, DiMauro S. New insights in the field of muscle glycogenoses. Curr Opin Neurol. 2013;26(5):544\u201353.","journal-title":"Curr Opin Neurol"},{"issue":"1","key":"473_CR80","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1212\/WNL.30.1.31","volume":"30","author":"ES Sherard Jr","year":"1980","unstructured":"Sherard ES Jr, Steiman GS, Couri D. Treatment of childhood epilepsy with valproic acid: results of the first 100 patients in a 6-month trial. Neurology. 1980;30(1):31\u20135.","journal-title":"Neurology"},{"issue":"30","key":"473_CR81","doi-asserted-by":"crossref","first-page":"27586","DOI":"10.1074\/jbc.M303740200","volume":"278","author":"N Detich","year":"2003","unstructured":"Detich N, Bovenzi V, Szyf M. Valproate induces replication-independent active DNA demethylation. J Biol Chem. 2003;278(30):27586\u201392.","journal-title":"J Biol Chem"},{"issue":"5","key":"473_CR82","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/S0960-8966(97)00062-X","volume":"7","author":"P Tan","year":"1997","unstructured":"Tan P, et al. A splice-site mutation causing ovine McArdle\u2019s disease. Neuromuscul Disord. 1997;7(5):336\u201342.","journal-title":"Neuromuscul Disord"},{"issue":"2","key":"473_CR83","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.nmd.2013.10.003","volume":"24","author":"JM Howell","year":"2014","unstructured":"\u2022\u2022 Howell JM, et al. Phosphorylase re-expression, increase in the force of contraction and decreased fatigue following notexin-induced muscle damage and regeneration in the ovine model of McArdle disease. Neuromuscul Disord. 2014;24(2):167\u201377. This study shows regeneration of muscle fibres after necrosis induced by intramuscular injections of notexin in a natural ovine model of McArdle disease.","journal-title":"Neuromuscul Disord"},{"issue":"2","key":"473_CR84","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.nmd.2014.10.002","volume":"25","author":"JM Howell","year":"2015","unstructured":"\u2022\u2022 Howell JM, et al. Investigating sodium valproate as a treatment for McArdle disease in sheep. Neuromuscul Disord. 2015;25(2):111\u20139. This study found effect of treatment with valproic acid on phosphorylase expression in muscle cells from the McArdle mouse model.","journal-title":"Neuromuscul Disord"},{"issue":"9646","key":"473_CR85","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/S0140-6736(08)61555-X","volume":"372","author":"AT Ploeg van der","year":"2008","unstructured":"van der Ploeg AT, Reuser AJ. Pompe\u2019s disease. Lancet. 2008;372(9646):1342\u201353.","journal-title":"Lancet"},{"issue":"3","key":"473_CR86","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ymgme.2012.09.015","volume":"107","author":"AT Ploeg van der","year":"2012","unstructured":"van der Ploeg AT, et al. Open-label extension study following the late-onset treatment study (LOTS) of alglucosidase alfa. Mol Genet Metab. 2012;107(3):456\u201361.","journal-title":"Mol Genet Metab"},{"issue":"1","key":"473_CR87","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1096\/fj.12-207472","volume":"27","author":"S Li","year":"2013","unstructured":"Li S, et al. Adjunctive beta2-agonists reverse neuromuscular involvement in murine Pompe disease. FASEB J. 2013;27(1):34\u201344.","journal-title":"FASEB J"}],"container-title":["Current Treatment Options in Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11940-017-0473-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-017-0473-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-017-0473-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,3]],"date-time":"2019-10-03T19:37:54Z","timestamp":1570131474000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11940-017-0473-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,21]]},"references-count":87,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["473"],"URL":"https:\/\/doi.org\/10.1007\/s11940-017-0473-2","relation":{},"ISSN":["1092-8480","1534-3138"],"issn-type":[{"value":"1092-8480","type":"print"},{"value":"1534-3138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,21]]},"article-number":"37"}}